APZ-2 (RHEACELL)

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameAPZ-2 (RHEACELL)
Drug Alias Nameallo-APZ2-CVUallo-APZ2-DFUALLO-APZ2-PAODallo-APZ2-OTSallo-APZ-2 +[6] 
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionATP-binding cassette transporter modulators
TargetsATP-binding cassette transporter
Therapy Area/IndicationsSkin UlcerEpidermolysis Bullosa DystrophicaEpidermolysis Bullosa +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesSlovakia +[18] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesRheacell Gmbh & Co Kg
China Registration ClassN/A

Develop Information

Active CompaniesTiceba GmbhRheacell Gmbh & Co Kg
Inactive CompaniesN/A
Active IndicationsSkin UlcerEpidermolysis Bullosa DystrophicaEpidermolysis Bullosa +[4] 
Inactive IndicationsAcute-On-Chronic Liver Failure

Other Information

ATC CodeN/A
Related LinksN/A